EP01.07-001 Surveillance with FDG PET/CT after Completion of Therapy for NSCLC: A Status Update on Inclusion in the SUPE_R Trial

K. Guldbrandsen, K. Skougaard, T.R. Rasmussen, B. Sørensen, L.S. Mortensen, Z. Saghir, S. Borissova, G. Persson, H. Skuladottir, S. Thisaruban, U. Bødtger, S.H. Schwaner, L.H. Land, O. Gerke, C.B. Laursen,L.B. Ahlborn, M. Pøhl, C.N. Meyer, J. Ehlers, M.S. Christophersen

Journal of Thoracic Oncology（2022）

引用 0|浏览0

暂无评分

摘要

Even after completion of curative treatment for non-small cell lung cancer (NSCLC), patients have a high risk of recurrence and consequently, active surveillance is recommended. The SUPE_R trial is an ongoing trial, designed to explore whether surveillance with F-18 fluoro-deoxy-glucose positron emission tomography/computed tomography (FDG PET/CT) and cell-free tumor DNA sequencing (ctDNA) can improve recurrence detection and increase the number of treatable relapses.

查看译文

关键词

nsclc,fdg pet/ct,therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要